Outlook Therapeutics (XTER:41O) Total Operating Expense: €51.04 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Outlook Therapeutics Total Operating Expense?

Outlook Therapeutics XTER:41O 18 Total Operating Expense is €51.04 Mil as of Mar. 2026. GuruFocus rates XTER:41O with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Outlook Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was €12.11 Mil. Outlook Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €51.04 Mil.

Outlook Therapeutics Total Operating Expense Related Terms

Outlook Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Total Operating Expense Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.97 63.70 49.78 64.60 57.19

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.46 14.58 13.89 10.46 12.11

Outlook Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €51.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €51.04 Mil mean?
Outlook Therapeutics (XTER:41O) has a Total Operating Expense of €51.04 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' Total Operating Expense too high?
Outlook Therapeutics' current Total Operating Expense is €51.04 Mil. Overall, Outlook Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Total Operating Expense compare to FULC and OBIO?
Outlook Therapeutics' Total Operating Expense of €51.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Total Operating Expense is €51.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (XTER:41O) has a current Total Operating Expense of €51.04 Mil. The current Total Operating Expense is €51.04 Mil. Outlook Therapeutics' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Outlook Therapeutics (XTER:41O), the current Total Operating Expense is €51.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges OTLK:USA41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.